The Malmberg lab partner in major cancer immunotherapy project
Karl-Johan Malmberg
The Malmberg Lab is one of four partners in project that recently was awarded 31 MSEK to study and develop new technologies for cancer immunotherapy. The constellation is led by Professor Bjorn Onfelt at the Royal Institute of Technology in Sweden.
The team focus on T and NK cells and their interactions with tumor cells in both 2D and 3D models.
“One of the most exciting things with this collaboration is the interdisciplinary collaboration between biologists, clinical scientists and phycisists”, says Kalle Mamberg, who holds a Visiting Professor position at the Karolinska Institute.
The key challenge is to identify the right cells for the job of eliminating tumor cells. Onfelt Lab has developed a microchip screening platform with 30.000 wells measuring 22x22micrometer. The confined area and multiple wells allows visualization and quantification of multiple, serial interactions using advanced confocal microscopy. It holds potential to identify subpopulations of cells with increased killing capacity.
From major journals, first or last author from the Institute for Cancer Research
Hurley JH, Coyne AN, Miączyńska M, Stenmark H(2025) The expanding repertoire of ESCRT functions in cell biology and disease Nature(in press) DOI 10.1038/s41586-025-08950-y, PubMed 40562928
Thulin MH, Ramberg H, Nielsen HK, Grytli HH, Sivanesan S, Pandya AD, Seip K, Andressen KW, Linder A, Øijordsbakken M, Poutanen M, Katz B, Halvorsen B, Mælandsmo GM, Taskén KA(2025) Beta-blockers prolong response to androgen deprivation therapy in prostate cancer through modulation of the neuro-immuno-oncology axis J Transl Med, 23(1), 672 DOI 10.1186/s12967-025-06644-7, PubMed 40528241
Singh R, Kyte JA(2025) STEAP1: a promising target in prostate cancer therapy Trends Cancer(in press) DOI 10.1016/j.trecan.2025.05.007, PubMed 40527692
Pagui ECK, Brant SB, Svendsen K, Frigessi A, Helland Å, Thoresen S, Jonasson C(2025) Comparative Effectiveness of Atezolizumab, Nivolumab and Pembrolizumab in Second-Line Treatment of Advanced Non-Small Cell Lung Cancer Pharmacoepidemiol Drug Saf, 34(7), e70181 DOI 10.1002/pds.70181, PubMed 40552731
Hurley JH, Coyne AN, Miączyńska M, Stenmark H(2025) The expanding repertoire of ESCRT functions in cell biology and disease Nature(in press) DOI 10.1038/s41586-025-08950-y, PubMed 40562928
Kranjec C, Oftedal TF, Ovchinnikov KV, da Silva Duarte V, Hermansen S, Kaus-Drobek M, Sabała I, Porcellato D, Carlsen H, Kjos M(2025) An antibiotic-free antimicrobial combination of bacteriocins and a peptidoglycan hydrolase: in vitro and in vivo assessment of its efficacy Appl Environ Microbiol, e0243324(in press) DOI 10.1128/aem.02433-24, PubMed 40552825